Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

3 Stocks Peter Lynch Would Love

By Rich Duprey - Nov 22, 2019 at 6:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These are businesses with great growth potential that are trading at significant discounts.

There's a very good reason Peter Lynch is an investing legend: For the 13 years he ran the Fidelity Magellan Fund, he averaged a 29% annual return that consistently more than doubled the return of the S&P 500.

He published two books that shared his investing philosophy, One Up on Wall Street and Beating the Street, which give the average investor the tools he used to rack up his amazing record. What made these books so popular is that Lynch showed that investing successfully wasn't rocket science, but something anyone could achieve.

Older woman with laptop

Image source: Getty Images.

As an investor, you want a company that brings something extra to the table, making it a better business than the competition, which is often a sign it has smart management. That's a key ingredient for a winning investment, though you don't want to overpay for the privilege of buying the stock. With that in mind, here are three companies that Peter Lynch might like if he were still guiding Magellan today.

Gaining altitude once more

Over the past year or so, AerCap ( AER -2.75% ) has faced pockets of turbulence, including the grounding of every single 737-MAX in Boeing's fleet, some relatively recent airline bankruptcies, a weakening Chinese market, and rate pressure from competition. Yet the aircraft leasing specialist is flying high in 2019, with shares rising 51% year to date as its investments in new technology aircraft continue to pay off.

CEO Aengus Kelly told analysts on AerCap's third-quarter earnings conference call, "We have spent more money than anyone in the world on acquiring new technology assets" over the last five years, but it's also been selling its older airplanes, reducing the age of its fleet down to 6.2 years from 6.6 last year.

More importantly, Kelly said AerCap consistently realizes an 8% gain on aircraft sold, allowing it to achieve a 30% return on book equity for the aircraft, a premium AerCap has enjoyed for the last 13 years.

Despite the stock's gains, AerCap's shares are still cheap, trading at a discount to the company's book value and under eight times trailing and estimated earnings. The airline industry is cyclical, but AerCap is one of those businesses with management bringing more to the table while managing its fleet, capital, and liquidity. And it still offers a very attractive price.

Under the microscope

Cancer biotech Exelixis ( EXEL -2.32% ) has moved in the opposite direction of AerCap, as its stock has lost 35% of its value from its 52-week high, though it's only off 16% year to date.

Much of the worry has centered on whether Exelixis has reached a plateau on sales of Cabometyx, its advanced liver and kidney cancer therapy. Third-quarter product revenue, which is mostly derived from Cabometyx sales, rose almost 18% from the year-ago period, hitting $191 million. But that was down slightly from the $193 million generated in the second quarter, suggesting U.S. Food and Drug Administration approval of combination treatments from Merck and Pfizer are eating into sales and will inhibit growth.

But Exelixis partnered with Bristol-Myers Squibb ( BMY 2.46% ) to develop its own Cabometyx-based combination therapy using Opdivo, which should help reignite sales growth if it gains approval next year. Still, cabozantinib (which Cabometyx is the branded version of) is the leading tyrosine kinase inhibitor prescribed for advanced kidney cancer, and approval for new indications may offset any competitive blows.

At eight times trailing earnings and 17 times next year's estimates, Exelixis is giving investors a discount, particularly when you consider that analysts expect the biotech to expand earnings 46% annually for the next three to five years. With the stock going for just 10 times the free cash flow it produces, Exelixis looks like a bargain.

An opportunity big enough to drive a truck through

The stock of carrier XPO Logistics ( XPO -2.94% ) was crushed by the news that Amazon.com was pulling a significant amount of business from the company as it builds out its own transportation and logistics services (with the expectation the rest would soon follow). XPO has spent the last year driving home the point that its business was not all about Amazon, and the market finally responded, doubling shares off their lows.

CEO Bradley Jacobs told analysts the entire management team is fixated on "executing on 10 major levers to significantly improve our profit over the next several years," most of which are centered around its technology advantage. Together they could improve profits by up to $1 billion by 2022.

If there's one thing Jacobs is known for, it's launching a company and then rolling up the entire industry under its umbrella and turning it into an industry leader. He did it with waste hauler United Waste Systems and equipment rental specialist United Rentals. He's doing it with XPO as well, but he hit the pause button as the Amazon announcement reverberated throughout the company.

Jacobs has since said the acquisition process is open again, and as other players have been weakened, XPO Logistics has a chance to buy up rivals at a discount. Its own stock is offering investors a discount, trading at a fraction of its revenue and long-term earnings growth estimates. Analysts see XPO expanding earnings at better than a 25% annual average rate for the foreseeable future, meaning this company could still be shifting into a higher gear.

 
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$16.40 (-2.32%) $0.39
XPO Logistics, Inc. Stock Quote
XPO Logistics, Inc.
XPO
$70.31 (-2.94%) $-2.13
AerCap Holdings N.V. Stock Quote
AerCap Holdings N.V.
AER
$54.50 (-2.75%) $-1.54
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$54.95 (2.46%) $1.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.